Search Results

You are looking at 101 - 110 of 199 items for :

  • "Metastatic breast cancer" x
Clear All
Full access

0120060 10.6004/jnccn.2014.0007 Use and Duration of Chemotherapy in Patients With Metastatic Breast Cancer According to Tumor Subtype and Line of Therapy Seah Davinia S.E. a MD, MPH Luis Ines Vaz a MD Macrae Erin b MD Sohl Jessica a

Full access

jnccn18113 10.6004/jnccn.2018.7090 Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer Xi Jing a b MD, MPH Oza Aabha a MD Thomas Shana a MS Ademuyiwa Foluso a MD, MPH

Full access

NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer Rocque Gabrielle B. a b MD, MSPH Williams Courtney P. b MPH Jackson Bradford E. c PhD Ingram Stacey A. b MEd Halilova Karian I

Full access

Michael Auerbach and Harold Ballard

Edited by Kerrin G. Robinson

. Leyland-Jones B Semiglazov V Pawlicki M . Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study . J Clin Oncol 2005 ; 23 : 5960 – 5972

Full access

Aparna Parikh, Chloe Atreya, W. Michael Korn and Alan P. Venook

-amplified mCRC. In HERACLES, HER2 positivity was defined as 3+ or 2+ by IHC or FISH-positive (defined by a HER2:CEP17 ratio >2 in >50% of cells). Lapatinib is approved in combination with chemotherapy in patients with metastatic breast cancer who have

Full access

Jaideep Sandhu, Chongkai Wang and Marwan Fakih

.18632/oncotarget.23054 29371924 17. Kida K , Lee J , Liu H , . Changes in the expression of HER2 and other genes in HER2-positive metastatic breast cancer induced by treatment with ado-trastuzumab emtansine and/or pertuzumab/trastuzumab [abstract

Full access

Melinda L. Telli, William J. Gradishar and John H. Ward

sampling for identifying mutations. 7 Alpelisib is expected to be approved soon, at which time it will be added to the guidelines, Dr. Gradishar said. Triple-Negative Metastatic Breast Cancer Until recently, the NCCN Guidelines recommended numerous lines

Full access

Virginia G. Kaklamani and William J. Gradishar

carboplatin in triple-negative metastatic breast cancer. 17 Furthermore, the AFFINITY trial is underway and has completed accrual, whereas an adjuvant phase III clinical trial incorporating carboplatin in TNBC is planned but has not yet opened to accrual

Full access

Bishal Gyawali, Elvira D’Andrea, Jessica M. Franklin and Aaron S. Kesselheim

2012 ; 367 : 1783 – 1791 . 23020162 10.1056/NEJMoa1209124 23. Krop IE , LoRusso P , Miller KD , . A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were

Full access

.5 CLO19-050 CLO19-050 CLO19-050 CLO19-050 jnccn20187150 10.6004/jnccn.2018.7150 CLO19-051: CDK 4/6 Inhibitor-Associated Hematologic Toxicities and Febrile Neutropenia in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer